Plain-English translation of NCT05646511 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new chemotherapy combination called (three drugs together) compared to the standard two-drug combination called , both given after short-course radiation therapy for advanced rectal cancer. The goal is to see if the three-drug treatment helps more patients achieve a complete response to therapy, which might allow them to skip surgery and preserve normal bowel function. Both groups receive the same radiation, but differ in the chemotherapy drugs given afterward.
Currently, many patients with advanced rectal cancer need surgery to remove part of their colon and rectum, which can affect bowel control and quality of life. Recent studies suggest that adding a third chemotherapy drug might help more patients achieve a complete response to treatment, potentially allowing them to avoid surgery altogether while maintaining better bowel function and quality of life.
You likely qualify if…
You likely don't qualify if…
You will receive five short radiation treatments over one week, followed by six cycles of chemotherapy (one cycle every 3 weeks). Depending on how your cancer responds, you may then either have surgery or skip surgery if your cancer disappears completely. After treatment ends, you will have regular follow-up visits every 4 months for 2 years, then every 6 months for another 3 years, including imaging scans, colonoscopy, and blood tests to monitor for any signs of cancer returning.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
Japan